U.S. Electrical Stock News

If you are wondering whether NuScale Power's current share price reflects its true worth, this article will help you size up the stock using several valuation tools. The stock recently closed at US$11.87, with returns of 0.4% over 7 days, 16.9% over 30 days, a 27.2% decline year to date, a 32.8% decline over 1 year, 47.6% over 3 years and 19.8% over 5 years. This gives you a wide range of outcomes to think about. Recent coverage has focused on NuScale Power's role in nuclear energy...

Guardant Health’s Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for VEPPANU, a therapy for ER+/HER2- advanced breast cancer with ESR1 mutations. This is the third ESR1 companion diagnostic approval tied to Guardant360 CDx, further linking the test to targeted breast cancer treatments. The new approval broadens the clinical use of Guardant360 CDx and deepens Guardant Health’s ties with pharmaceutical partners. For investors tracking Guardant Health...

Alkermes Q1 2026 earnings: setting the stage Alkermes (ALKS) heads into Q1 2026 following its Q4 2025 report, where revenue was US$384.5 million and basic EPS came in at US$0.30, with net income excluding extra items of US$49.3 million. Over recent quarters, the company has reported revenue of US$429.99 million in Q4 2024, US$390.7 million in Q2 2025, and US$394.2 million in Q3 2025. Quarterly basic EPS over that period was US$0.90 in Q4 2024, US$0.50 in Q3 2025, and US$0.30 in Q4 2025. These...

Seadrill stock snapshot after recent performance Seadrill (SDRL) has drawn fresh attention after recent trading, with the stock last closing at US$48.90 and showing mixed short term returns, including a 0.9% decline over the past day and 1.8% decline over the past week. See our latest analysis for Seadrill. While Seadrill’s 1 day and 7 day share price returns are slightly negative, the 30 day and 90 day share price returns of 7.2% and 23.5%, together with a 1 year total shareholder return of...

Revvity Q1 2026 earnings snapshot Revvity (RVTY) has just put fresh numbers on the table, with recent quarters showing revenue between US$664.8 million and US$772.1 million and basic EPS ranging from US$0.35 to US$0.85 as the company heads into its Q1 2026 update. Over the past year, revenue has been recorded from US$684.0 million in Q3 2024 up to US$772.1 million in Q4 2025, while basic EPS prints in that stretch run from US$0.35 to US$0.85, giving investors a clear view of how the top line...

Two Harbors Investment (NYSE:TWO) is the subject of a takeover battle involving competing bids from UWM Holdings and CrossCountry Mortgage. The board of NYSE:TWO has rejected multiple acquisition attempts from UWM Holdings and is backing a fully financed, all-cash offer from CrossCountry Mortgage. The contest now centers on a shareholder vote, proxy solicitations, and competing arguments about value, deal structure, and execution risk. For you as a NYSE:TWO shareholder, this is not a...

Wondering if Ally Financial at around US$43 per share still offers value, or if most of the easy gains are behind it, starts with understanding what the current price is actually reflecting. The stock has had mixed recent returns, with a 2.7% decline over the last week, an 8.5% gain over the last month, a 5.6% decline year to date, and a 36.8% return over the last year alongside an 88.9% three year return and a 2.9% five year decline. Recent coverage has focused on how Ally Financial fits...

Avista’s Q1 2026 earnings in focus Avista (AVA) has rolled into Q1 2026 on the back of a solid run through 2025, capped by Q4 revenue of US$533 million and basic EPS of US$0.87, alongside trailing 12 month EPS of US$2.38 on US$1.96 billion of revenue. Over recent quarters, the company has seen revenue hold in a US$394 million to US$617 million range while quarterly EPS moved between US$0.17 and US$0.98. The trailing net profit margin is 9.8% compared with 9.3% a year earlier, which puts the...

In the past quarter, Adaptive Biotechnologies reported first‑quarter 2026 revenue of US$70.87 million, up from US$52.44 million a year earlier, while narrowing its net loss to US$20.03 million and reducing basic loss per share from US$0.20 to US$0.13. The results were powered by Minimal Residual Disease testing, with clonoSEQ volumes rising strongly and management raising full‑year 2026 MRD revenue guidance to US$260–US$270 million, underscoring the segment’s growing importance to the...

AGCO (AGCO) has just opened Q1 2026 earnings season with recent quarterly numbers that plot a sharp swing in profitability, moving from a Q4 2024 net loss of US$255.7 million on US$2,887.3 million of revenue and EPS of US$3.43 loss, to Q4 2025 net income of US$95.5 million on US$2,920.2 million of revenue and EPS of US$1.29. Over the same period, trailing twelve month EPS shifted from a US$5.69 loss on US$11.7 billion of revenue to US$9.76 on US$10.1 billion. Revenue moved from US$2,599.3...

In late April 2026, Opera Limited reported past first-quarter 2026 results showing sales of US$175.77 million and net income of US$24.79 million, alongside higher basic and diluted EPS of US$0.27 from continuing operations. On the same day, Opera raised its full-year 2026 revenue outlook to US$727 million–US$740 million and projected robust double-digit year-over-year growth for both the second quarter and the full year, highlighting management’s confidence in the business. With Opera...

Investors may be wondering if ConocoPhillips at around US$123.32 still offers value after a strong run, or if recent enthusiasm has already been priced in. The stock has seen a 27.5% return year to date and 45.5% over the last year, even though the last 7 days and 30 days showed returns of a 0.8% decline and a 5.5% decline, respectively. Recent coverage has focused on ConocoPhillips as a major integrated energy producer, with attention on how it is positioning its portfolio and capital...

AnaptysBio recently reported that the Delaware Chancery Court dismissed Tesaro’s anticipatory breach of contract claim over their Jemperli collaboration, while CEO Daniel Faga is set to discuss the company’s royalty assets at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026. This legal outcome, combined with a stronger earnings outlook highlighted by an upgraded Zacks rank, strengthens AnaptysBio’s position around its Jemperli-related royalty rights. We’ll now...

In the first quarter of 2026, Molson Coors Beverage Company reported year-on-year increases in sales to US$2,717.9 million, revenue to US$2,351.1 million, and net income to US$151.3 million, with basic earnings per share from continuing operations rising to US$0.80. The company coupled these stronger results with a three-year US$450 million cost-savings program, continued integration of Monaco Cocktails, and reaffirmed full-year 2026 guidance despite ongoing volume and cost pressures. We’ll...

AGNC Investment (AGNC) opened 2026 with a softer quarter, reporting Q1 total revenue of a loss of US$114 million and a basic EPS loss of US$0.17, set against trailing twelve month revenue of US$1.6 billion and EPS of US$1.22. Over recent periods the company has seen quarterly revenue move from US$154 million in Q4 2024 to US$995 million in Q4 2025, with basic EPS shifting from US$0.10 to US$0.83 over the same span. Trailing twelve month revenue rose from US$973 million in Q4 2024 to US$1.8...

In late April 2026, The Scotts Miracle-Gro Company reported past second-quarter results showing US$1,459.5 million in sales and US$238.6 million in net income, with both basic and diluted earnings per share from continuing operations increasing year over year. Alongside these results, Scotts Miracle-Gro reaffirmed its fiscal 2026 outlook and outlined its SMG 2.0 plan targeting meaningful growth, higher margins, lower leverage, and a multi-year share repurchase program that together could...

Wondering whether Scotts Miracle-Gro at around US$60.06 is priced for a recovery or still carrying too much risk? This article focuses on what the current share price might be implying about value. The stock has been volatile recently, with a 7 day return of an 8.1% decline, a 30 day return of a 6.0% decline, and a 1 year return of 14.3%, while the 5 year return sits at a 70.3% decline. Recent headlines around Scotts Miracle-Gro have focused on the company’s position in consumer lawn and...

Elevance Health (NYSE:ELV) is rolling out nationwide mental health access and early intervention programs through community partnerships and digital tools. The Elevance Health Foundation currently has $23 million in active grants focused on mental health initiatives across the United States. These efforts aim to connect members with earlier, community-based care that complements the company’s existing clinical programs. For investors watching NYSE:ELV, this push into broader mental health...

This article examines whether Cohen & Steers at US$69.54 is offering fair value and breaks down what the current price may be indicating about the stock. The share price is up 0.9% over the last week and 11.0% over the past month. Year to date it is up 9.4%, while the 1 year return stands at a 6.4% decline, set against a 3 year return of 42.2% and a 5 year return of 17.1%. Recent headlines have focused on Cohen & Steers in the context of the wider Capital Markets sector, with attention on...

IAC (IAC) has just posted its Q1 2026 scorecard, and the latest trailing twelve month figures show total revenue of about US$2.4 billion with a basic EPS loss of US$1.49 and net income excluding extra items of US$119.31 million in losses. Over recent quarters the company has seen quarterly revenue move from US$642 million in Q3 2024 to US$721.44 million in Q4 2024, then to US$570.49 million in Q1 2025 and US$645.98 million in Q4 2025. Basic EPS shifted from a loss of US$3.40 in Q3 2024 to a...

Viper Energy Q1 2026 earnings snapshot Viper Energy (VNOM) opened Q1 2026 with mixed signals, as trailing twelve month revenue sat at US$1.3 billion against a loss of US$69 million, translating into trailing EPS of US$0.48. The most recent quarterly print in Q4 2025 showed revenue of US$411 million and a net loss of US$103 million, or EPS of US$0.61. Over the past few reported quarters, revenue has moved from US$232 million in Q1 2025 to US$283 million in Q2 2025, US$399 million in Q3 2025...

In April 2026, Daily Racing Form, a subsidiary of Affinity Interactive, announced multi-year exclusive print distribution agreements with American Wagering and Boyd Gaming, making it the sole provider of racing publications across key Las Vegas casinos including Boyd’s Gold Coast, Orleans and Sam’s Town properties. The tie-up deepens Boyd Gaming’s connection to core racing customers ahead of marquee events such as the Kentucky Derby, while aligning with Apex Hospitality’s broader push to...

Investors may be wondering whether Oppenheimer Holdings at around US$99 a share still offers value, or if most of the opportunity has already been priced in. The stock has been volatile recently, with an 11.3% pullback over the last 7 days alongside a 9.3% gain over 30 days, and returns of 36.8% year to date and 69.4% over the past year. Recent headlines around capital markets activity and trading conditions have kept investor attention on brokers and financial services stocks, including...

If you are wondering whether HP's current share price reflects its real value, you are not alone. This article walks through what the latest data says about where the stock stands today. HP shares last closed at US$21.15, with recent returns of 7.2% over 7 days and 8.4% over 30 days, but a 4.4% decline year to date and a 13.3% decline over 1 year. This frames an important question about whether the recent rebound changes the risk and reward trade off. Recent news coverage has focused on HP's...